These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37942138)

  • 1. Original research: initial development of a pragmatic tool to estimate cognitive decline risk focusing on potentially modifiable factors in Parkinson's disease.
    Carlisle TC; Medina LD; Holden SK
    Front Neurosci; 2023; 17():1278817. PubMed ID: 37942138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia Risk Prediction in a Longitudinal Geriatric Parkinson's Disease Cohort: Evaluation and Application of the Montreal Parkinson Risk of Dementia Scale.
    Bohn L; McFall GP; Gee M; Postuma RB; Dixon RA; Camicioli R
    Can Geriatr J; 2023 Mar; 26(1):176-186. PubMed ID: 36865405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LIBRA Index in Relation to Cognitive Function, Functional Independence, and Psycho-Behavioral Symptoms in a Sample of Non-Institutionalized Seniors at Risk of Dementia.
    Franchini F; Musicco M; Ratto F; Storti G; Shofany J; Caltagirone C; Di Santo SG
    J Alzheimers Dis; 2019; 72(3):717-731. PubMed ID: 31640092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyle for brain health and cognitive functioning in midlife to early late-life New Zealanders: Utility of the LIBRA index.
    Röhr S; Stephens C; Alpass F
    Int J Geriatr Psychiatry; 2024 May; 39(5):e6091. PubMed ID: 38666629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CogDrisk, ANU-ADRI, CAIDE, and LIBRA Risk Scores for Estimating Dementia Risk.
    Huque MH; Kootar S; Eramudugolla R; Han SD; Carlson MC; Lopez OL; Bennett DA; Peters R; Anstey KJ
    JAMA Netw Open; 2023 Aug; 6(8):e2331460. PubMed ID: 37647064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the LIBRA Index in Relation to Cognitive Functioning in a Clinical Health Seeking Sample.
    Pons A; LaMonica HM; Mowszowski L; Köhler S; Deckers K; Naismith SL
    J Alzheimers Dis; 2018; 62(1):373-384. PubMed ID: 29439337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender and Educational Differences in the Association between Lifestyle and Cognitive Decline over 10 Years: The Doetinchem Cohort Study.
    Deckers K; Nooyens A; van Boxtel M; Verhey F; Verschuren M; Köhler S
    J Alzheimers Dis; 2019; 70(s1):S31-S41. PubMed ID: 30507570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifiable dementia risk score to study heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in the preDIVA trial using the LIBRA index.
    van Middelaar T; Hoevenaar-Blom MP; van Gool WA; Moll van Charante EP; van Dalen JW; Deckers K; Köhler S; Richard E
    Alzheimers Res Ther; 2018 Jun; 10(1):62. PubMed ID: 29960597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of the Lifestyle for Brain Health Index With Structural Brain Changes and Cognition: Results From the Maastricht Study.
    Heger IS; Deckers K; Schram MT; Stehouwer CDA; Dagnelie PC; van der Kallen CJH; Koster A; Eussen SJPM; Jansen JFA; Verhey FRJ; van Boxtel MPJ; Köhler S
    Neurology; 2021 Sep; 97(13):e1300-e1312. PubMed ID: 34433680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
    Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study (EPAD LCS).
    Saunders TS; Protsiv M; Jenkins ND; Solomon A; Blennow K; Ritchie C; Muniz-Terrera G
    J Prev Alzheimers Dis; 2023; 10(3):543-550. PubMed ID: 37357296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index.
    Deckers K; Köhler S; Ngandu T; Antikainen R; Laatikainen T; Soininen H; Strandberg T; Verhey F; Kivipelto M; Solomon A
    Alzheimers Dement; 2021 Jul; 17(7):1205-1212. PubMed ID: 33403822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Socioeconomic Inequalities in Cognitive Functioning Only to a Small Extent Attributable to Modifiable Health and Lifestyle Factors in Individuals Without Dementia.
    Röhr S; Pabst A; Baber R; Engel C; Glaesmer H; Hinz A; Schroeter ML; Witte AV; Zeynalova S; Villringer A; Löffler M; Riedel-Heller SG
    J Alzheimers Dis; 2022; 90(4):1523-1534. PubMed ID: 36278347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease.
    Forbes E; Tropea TF; Mantri S; Xie SX; Morley JF
    Mov Disord Clin Pract; 2021 Feb; 8(2):254-263. PubMed ID: 33553496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term dementia risk prediction by the LIBRA score: A 30-year follow-up of the CAIDE study.
    Deckers K; Barbera M; Köhler S; Ngandu T; van Boxtel M; Rusanen M; Laatikainen T; Verhey F; Soininen H; Kivipelto M; Solomon A
    Int J Geriatr Psychiatry; 2020 Feb; 35(2):195-203. PubMed ID: 31736136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a multidomain intervention against cognitive decline on dementia risk profiles - Results from the AgeWell.de trial.
    Zülke AE; Pabst A; Luppa M; Oey A; Weise S; Fankhänel T; Kosilek RP; Schillok H; Brettschneider C; Czock D; Wiese B; Thyrian JR; Hoffmann W; Frese T; Gensichen J; König HH; Kaduszkiewicz H; Riedel-Heller SG
    Alzheimers Dement; 2024 Jul; ():. PubMed ID: 38967275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.